Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$----
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
Debt to Equity
--
ROE
--
ROCE
--
Div. Yield
--
Book Value
--
EPS
--
CFO
$-281.52 Mln
EBITDA
$--
Net Profit
$-293.74 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Gamida Cell (GMDAQ)
| -- | -- | -- | -- | -- | -- | -- |
|
BSE Sensex*
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Gamida Cell Ltd. researches, develops, and commercializes cell therapies. The company offers Omisirge (omidubicel-onlv), a cell therapy for use in treatment of patients with hematologic malignancies and severe aplastic anemia. Its product candidate... includes GDA-201, an investigational NK cell-based cancer immunotherapy, for the treatment of hematologic and solid tumors, as well as to treat follicular and diffuse large B-cell lymphomas which is in phase 1 of phase1/2 clinical trial. The company was incorporated in 1998 and is based in Boston, Massachusetts. Read more
President, CEO & Director
Ms. Abigail L. Jenkins M.S.
Chief Financial Officer
Ms. Mary Theresa Coelho M.B.A.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Gamida Cell Ltd (GMDAQ) is $0.02 (NASDAQ) as of 24-May-2024 12:55 EDT. Gamida Cell Ltd (GMDAQ) has given a return of --% in the last 1 years.
Gamida Cell Ltd (GMDAQ) has a market capitalisation of -- as on 24-May-2024. As per Value Research classification, it is a Small Cap company.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Gamida Cell Ltd (GMDAQ) and enter the required number of quantities and click on buy to purchase the shares of Gamida Cell Ltd (GMDAQ).
Gamida Cell Ltd. researches, develops, and commercializes cell therapies. The company offers Omisirge (omidubicel-onlv), a cell therapy for use in treatment of patients with hematologic malignancies and severe aplastic anemia. Its product candidate includes GDA-201, an investigational NK cell-based cancer immunotherapy, for the treatment of hematologic and solid tumors, as well as to treat follicular and diffuse large B-cell lymphomas which is in phase 1 of phase1/2 clinical trial. The company was incorporated in 1998 and is based in Boston, Massachusetts.
The CEO & director of Ms. Abigail L. Jenkins M.S.. is Gamida Cell Ltd (GMDAQ), and CFO & Sr. VP is Ms. Mary Theresa Coelho M.B.A..
There is no promoter pledging in Gamida Cell Ltd (GMDAQ).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Gamida Cell Ltd (GMDAQ) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Gamida Cell Ltd (GMDAQ) was $0 Mln.
